Supplementary Material for: Expert Statement: Pneumothorax Associated with One-Way Valve Therapy for Emphysema: 2020 Update

  • Jan Kocks (Contributor)
  • Pallav L. Shah (Contributor)
  • Rick Sue (Contributor)
  • Marlies van Dijk (Contributor)
  • Dirk Jan Slebos (Contributor)
  • Felix J. F. Herth (Contributor)
  • Hugo G. de Oliveira (Contributor)
  • D. Kyle Hogarth (Contributor)
  • Karin Slebos-Klooster (Contributor)
  • Arschang Valipour (Contributor)
  • Daniela Gompelmann (Contributor)
  • Gerard J. Criner (Contributor)



For selected patients with advanced emphysema, bronchoscopic lung volume reduction with one-way valves can lead to clinically relevant improvements of airflow obstruction, hyperinflation, exercise capacity, and quality of life. The most common complication of this procedure is pneumothorax with a prevalence of up to ±34% of the treated patients. Patients who develop a pneumothorax also experience meaningful clinical benefits once the pneumothorax is resolved. Timely resolution of a post-valve treatment pneumothorax requires skilled and adequate pneumothorax management. This expert panel statement is an updated recommendation of the 2014 statement developed to help guide pneumothorax management after valve placement. Additionally, mechanisms for pneumothorax development, risk assessment, prevention of pneumothorax, and outcomes after pneumothorax are addressed. This recommendation is based on a combination of the current scientific literature and expert opinion, which was obtained through a modified Delphi method.
Datum van beschikbaarheid1-jun.-2021
Uitgeverfigshare Academic Research System

Citeer dit